Seeds Investor LLC Sells 249 Shares of Penumbra, Inc. $PEN

Seeds Investor LLC decreased its position in Penumbra, Inc. (NYSE:PEN) by 18.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,101 shares of the company’s stock after selling 249 shares during the period. Seeds Investor LLC’s holdings in Penumbra were worth $283,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Penumbra by 5.0% during the 2nd quarter. Vanguard Group Inc. now owns 3,860,655 shares of the company’s stock valued at $990,760,000 after buying an additional 185,306 shares during the period. Geode Capital Management LLC raised its stake in shares of Penumbra by 2.6% during the second quarter. Geode Capital Management LLC now owns 706,404 shares of the company’s stock valued at $181,314,000 after acquiring an additional 17,772 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Penumbra by 437.0% during the first quarter. JPMorgan Chase & Co. now owns 703,634 shares of the company’s stock worth $188,159,000 after purchasing an additional 572,606 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of Penumbra by 0.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 322,030 shares of the company’s stock worth $80,726,000 after purchasing an additional 984 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Penumbra by 4.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 283,821 shares of the company’s stock worth $75,897,000 after purchasing an additional 12,247 shares during the last quarter. 88.88% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

PEN has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Penumbra in a research report on Wednesday. UBS Group set a $335.00 target price on Penumbra and gave the company a “buy” rating in a research note on Wednesday, July 30th. Needham & Company LLC restated a “buy” rating and set a $326.00 target price on shares of Penumbra in a report on Monday, October 27th. Wall Street Zen cut shares of Penumbra from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Finally, Wells Fargo & Company started coverage on shares of Penumbra in a research report on Tuesday. They set an “underweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Penumbra has an average rating of “Moderate Buy” and an average price target of $305.69.

Insider Buying and Selling at Penumbra

In other news, Director Harpreet Grewal sold 186 shares of Penumbra stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $227.58, for a total transaction of $42,329.88. Following the completion of the transaction, the director directly owned 8,516 shares in the company, valued at approximately $1,938,071.28. This trade represents a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Johanna Roberts sold 600 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $266.98, for a total value of $160,188.00. Following the completion of the sale, the executive vice president directly owned 63,657 shares in the company, valued at approximately $16,995,145.86. This represents a 0.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 18,530 shares of company stock worth $4,961,586. Insiders own 4.20% of the company’s stock.

Penumbra Price Performance

PEN opened at $288.86 on Friday. The company has a current ratio of 6.75, a quick ratio of 4.04 and a debt-to-equity ratio of 0.02. The company has a market cap of $11.31 billion, a price-to-earnings ratio of 76.82, a price-to-earnings-growth ratio of 2.10 and a beta of 0.51. The stock has a fifty day simple moving average of $256.55 and a two-hundred day simple moving average of $257.79. Penumbra, Inc. has a 12-month low of $221.26 and a 12-month high of $310.00.

Penumbra (NYSE:PEN) last announced its earnings results on Wednesday, November 5th. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.07. The firm had revenue of $354.69 million for the quarter, compared to analysts’ expectations of $340.77 million. Penumbra had a net margin of 11.54% and a return on equity of 11.55%. The company’s quarterly revenue was up 17.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.85 EPS. Penumbra has set its FY 2025 guidance at EPS. Research analysts predict that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.